BTK Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

  Рет қаралды 4,105

PeerView Oncology

PeerView Oncology

Күн бұрын

Co-Chairs, Benjamin M. Greenberg, MD, MHS and Professor Anthony Traboulsee, MD, discuss multiple sclerosis in this CME/NCPD/CPE activity titled “Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach.” For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/CPE information, and to apply for credit, please visit us at PeerView.com/NXB865. CME/NCPD/CPE credit will be available until November 27, 2022.

Пікірлер
MS: A Most Unusual Disease  - Ben Thrower, M D - September 2015
55:09
Multiple Sclerosis Foundation
Рет қаралды 54 М.
Optogenetics: Illuminating the Path toward Causal Neuroscience
3:54:38
Harvard Medical School
Рет қаралды 1,8 МЛН
Happy birthday to you by Secret Vlog
00:12
Secret Vlog
Рет қаралды 6 МЛН
Walking on LEGO Be Like... #shorts #mingweirocks
00:41
mingweirocks
Рет қаралды 7 МЛН
BTK Inhibition and the Future of MS Management
32:36
PeerView CME
Рет қаралды 1 М.
Pulse Radiology MRI Live Registry Prep - April 3, 2022
3:46:46
Pulse Radiology
Рет қаралды 70 М.
Dr. Layne Norton: The Science of Eating for Health, Fat Loss & Lean Muscle
3:49:35
Understanding Progression in MS
1:06:15
Multiple Sclerosis Association of America
Рет қаралды 3,5 М.
Ben Thrower, MD: Update: New MS Treatments: NMSEAM 2023
1:02:29
Multiple Sclerosis Foundation
Рет қаралды 4,8 М.